Key Points {#FPar1}
==========

The ulcerative colitis treatment armamentarium includes 5-aminosalicylic acid compounds, corticosteroids, thiopurines, calcineurin inhibitors and monoclonal antibodies (mAbs).Therapeutic drug monitoring (TDM) of thiopurines, calcineurin inhibitors and mAbs is being applied in clinical practice.Factors associated with pharmacokinetics can be used when applying TDM, e.g. genetic polymorphism for thiopurines or tacrolimus, and body weight, albumin serum concentrations and antidrug antibodies for infliximab (IFX) therapy.

Introduction {#Sec1}
============

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) probably caused by a combination of genetic and environmental factors \[[@CR1]\]. The severity of UC can be classified as mild, moderate or severe depending on clinical (e.g. daily number of stools with or without blood, urgency), biochemical and endoscopic findings \[[@CR2], [@CR3]\]. According to the Montreal classification, the disease extent determined at endoscopy can be classified into three subgroups: involvement limited to the rectum (E1), involvement limited to the distal colon not exceeding the splenic flexure (E2), or involvement exceeding the splenic flexure (E3) \[[@CR4]\]. The precise etiology of UC is not known and 'cure' of this disease is not yet possible. Therefore, the primary therapeutic goal is to induce and maintain remission of the inflammation \[[@CR5]\]. The main treatment goals for UC include clinical remission, i.e. relief of symptoms, in combination with mucosal healing. According to the classic step-up approach, treatment of UC starts with administration of 5-aminosalicylic acid (5-ASA) compounds, followed by short-term use of corticosteroids, immunomodulators and biologicals (Fig. [1](#Fig1){ref-type="fig"}). As a counterpart to the step-up approach, treatment with immunomodulators and/or biologicals can be applied as therapy of first choice according to the top-down approach \[[@CR6], [@CR7]\]. Patients with acute extensive disease activity (Montreal classification E3) could potentially benefit from a top-down approach \[[@CR7]\]. Therapeutic drug monitoring (TDM) is increasingly used in the treatment of UC to maximize the clinical benefit of therapeutic agents \[[@CR8]--[@CR11]\]. TDM is defined as measuring a drug concentration, interpreting this value using pharmacokinetic principles, followed by making decisions about possible dose adjustments or dosing intervals in order to optimize treatment \[[@CR12]\]. This review provides an overview of the pharmacokinetic and pharmacodynamic considerations in the treatment of UC.Fig. 1Classical step-up approach for ulcerative colitis

Methods {#Sec2}
=======

PubMed was searched for studies including only humans, using the following terms: ("inflammatory bowel disease" \[Mesh\] OR "ulcerative colitis" \[Mesh\]) AND ("pharmacokinetic\*" OR "pharmacodynamic\*"). Articles were selected based on relevance, and additional articles were obtained from their reference lists.

5-Aminosalicylic Acid (5-ASA) Compounds {#Sec3}
=======================================

The prodrug sulfasalazine was the first oral 5-ASA compound developed for the treatment of UC. After oral administration, sulfasalazine is split by colonic bacteria with the liberation of the pharmacologically active 5-ASA (mesalazine) and the pharmacologically inactive sulfapyridine \[[@CR13]\]. Since sulfapyridine is responsible for several side effects, mesalazine is preferably administered as a direct-acting agent or as a prodrug coupled to other vehicles, in the case of olsalazine. In the treatment of UC, 5-ASA compounds are used to both induce and maintain remission \[[@CR14]\]. In patients with mild to moderately active distal UC, topical treatment with mesalazine suppositories or enemas is the preferred initial treatment \[[@CR5], [@CR15], [@CR16]\]. Combined oral and topical 5-ASA treatment is preferred in patients with mild to moderately active left-sided colitis \[[@CR5]\].

Pharmacokinetic and Pharmacodynamic Considerations {#Sec4}
--------------------------------------------------

After oral and rectal administration of mesalazine, a considerable amount of the drug is excreted unabsorbed with the faeces \[[@CR17]\]. Mesalazine is unstable in gastric acid and rapidly absorbed in the small intestine, with approximately 20% reaching the terminal ileum and colon \[[@CR18], [@CR19]\]. With pH-dependent coatings and controlled-release formulations, premature absorption of mesalazine is prevented until the distal part of the bowel is reached. Absorbed mesalazine undergoes presystemic N-acetylation in intestinal mucosa and the liver. This pharmacologically inactive N-acetylated mesalazine is mainly excreted into the urine \[[@CR17], [@CR20]\]. After rectal administration, 10--35% of the drug is absorbed \[[@CR17]\], whereas after oral administration, depending on the dose and the type of formulation used, 15--67% of the drug is absorbed and excreted into the urine \[[@CR21]\]. Pharmacokinetic parameters are listed in Table [1](#Tab1){ref-type="table"}.Table 1Pharmacokinetic parameters of 5-ASA compoundsDrugDosePopulationC~max~ (µg/ml)T~max~ (h)Half-life (h)5-ASAAc-5-ASA5-ASAAc-5-ASASalofalk \[[@CR216]\]500 mg PO bidIBD patients--------1.4 ± 0.6^a^Pentasa \[[@CR217]\]Single-dose 500 mg POHealthyNot detected1.8 \[1.1--2.9\]^b^------Pentasa \[[@CR218]\]Single-dose 1000 mg POHealthy0.99 (53)^c^1.83 (44)^c^3.48 (53)^c^3.74 (47)^c^--Asacol \[[@CR219]\]800 mg tidHealthy1.2 \[0.5--7.0\]^b^1.9 \[1.0--5.5\]^b^------Mesalamine \[[@CR17]\]500 mg PO tid----------1.4 (0.7--2.4)^b^Mesalamine \[[@CR21]\]1.2 g PO qdHealthy1.1 \[0.1--8.6\]^b^2.2 \[1.4--8.7\]^b^------^a^Mean ± standard deviation^b^Median \[range\]^c^Mean (coefficient of variation, in %)*5*-*ASA* 5-aminosalicylic acid, *Ac*-*5*-*ASA* acetylated 5-aminosalicylic acid, *bid* twice daily, *C*~*max*~ maximum concentration, *IBD* inflammatory bowel disease, *PO* orally, *qd* once daily, *tid* three times daily, *T*~*max*~ time to reach maximum concentration

Mesalazine is metabolized locally by the intestinal N-acetyltransferase 1 (NAT1), whereas sulfapyridine, as part of the prodrug sulfasalazine, is metabolized by the hepatic N-acetyltransferase 2 (NAT2) \[[@CR16]\]. Both NAT1 and NAT2 genotypes do not predict response for mesalazine and sulfasalazine, respectively, in UC patients \[[@CR23]\].

5-ASA acts locally on the colonic epithelium and has multiple anti-inflammatory effects \[[@CR24]\]. Although the exact mechanism of action remains to be elucidated, the main mechanism includes inhibition of cyclooxygenase and lipoxygenase, subsequently leading to reduced production of prostaglandins and leukotrienes, respectively \[[@CR25]\]. Additionally, the nuclear receptor peroxisome proliferators-activated receptor ligand-γ (PPAR-γ) is activated by 5-ASA. PPAR-γ is a transcription factor that modulates inflammatory responses by inhibiting the production of tumor necrosis factor (TNF), amongst others \[[@CR18]\].

After oral and rectal administration, systemic concentrations of 5-ASA are low (\< 0.5 µg/ml) compared with intraluminal colonic concentrations, and have been shown to increase with higher oral 5-ASA doses \[[@CR17], [@CR21], [@CR24], [@CR26]--[@CR28]\]. Systemic exposure to 5-ASA was shown to be lower after rectal administration than after oral administration of the same dose \[[@CR28]\]. This might be due to the physiological absence of specific uptake transporters in intestinal mucosa. Lower systemic exposure after rectal administration could potentially reduce drug toxicity in comparison with oral drug delivery systems. Rectal mesalazine has been shown to be more effective, with clinical improvement rates superior to oral mesalazine in patients with distal UC \[[@CR29]\]. To evaluate the concentration--effect relationship of 5-ASA, local tissue measurement of 5-ASA is preferred because of the topical mechanism of action \[[@CR21]\]. Increasing the oral dose of delayed-release mesalazine from 1.2 to 2.4 g daily has been associated with an increase in rectal 5-ASA tissue concentrations \[[@CR21]\]. Furthermore, an inverse relationship between 5-ASA tissue concentrations and disease activity has been shown \[[@CR30]--[@CR32]\]. Likewise, lower mucosal levels of soluble interleukin (IL) receptor 2 were found, a marker of mucosal inflammation \[[@CR32]\]. This suggests that the dose-related effect of 5-ASA may depend on the concentration in the mucosa.

With sulfasalazine, multiple dosing per day was required to minimalize the risk of adverse events because of the toxic metabolite sulfapyridine. With the development of sulfapyridine-free 5-ASA compounds, clinical trials followed the same pharmacokinetic principle and the compounds were also administered by multiple dosing; however, a multiple dosing regimen is associated with nonadherence \[[@CR33]\]. Kruis et al. showed that once-daily dosing of mesalazine granules was as equally effective and safe as dosing three times per day \[[@CR34]\]. Additionally, Multi-Matrix System mesalazine (MMX^®^, LIALDA^®^, Asacol HD^®^) allows high-dose once-daily dosing and is proven to be well tolerated and effective for the treatment of mild to moderately active UC administered as 2.4 or 4.8 g/day \[[@CR35]--[@CR37]\]. Recently, high concentration tablets of mesalazine once daily were shown to be as equally effective as multiple doses of mesalazine daily to induce and maintain mucosal healing \[[@CR38]\].

Corticosteroids {#Sec5}
===============

Corticosteroids are potent anti-inflammatory drugs that are used for the treatment of various autoimmune and inflammatory diseases. Remission induction therapy with corticosteroids is appropriate in IBD patients with moderate to severe activity, and in patients with mild activity who are intolerant or refractory to 5-ASA compounds \[[@CR5], [@CR39]\]. According to the European Crohn's and Colitis Organisation (ECCO) guidelines, an appropriate regimen for moderately active disease is administration of oral prednisolone 40 mg/day for 1 week, lowering the daily dose by 5 mg each week and resulting in an 8-week course \[[@CR5]\]. For patients admitted with severe UC, initial treatment with intravenous corticosteroids is recommended, with methylprednisone 40--60 mg/day as a bolus infusion. Corticosteroids should not be used as maintenance treatment because of the high probability of developing adverse events and corticosteroid-dependent disease \[[@CR40], [@CR41]\].

Remission rates are significantly higher in UC patients receiving oral corticosteroids compared with placebo \[[@CR42]\]. Corticosteroids give a remission rate of up to 73% and a number needed to treat for remission of 2 in mild disease, and are therefore considered as effective for remission induction therapy \[[@CR43]\]. Corticosteroids bind to the glucocorticoid receptor, and the mechanism of action is based on inhibition of protein transcription and synthesis by affecting the stability of messenger RNA. Corticosteroids downregulate the production of the transcription factor NF-κB and many proinflammatory cytokines, such as IL-1, IL-6 and TNF \[[@CR44], [@CR45]\].

Pharmacokinetic and Pharmacodynamic Considerations {#Sec6}
--------------------------------------------------

Corticosteroids can be administered via different routes: intravenous, oral, and rectal formulations are available. Prednisone and budesonide are the most commonly used corticosteroids for the treatment of UC.

Prednisolone is the pharmacologically active metabolite of prednisone. Both compounds are rapidly absorbed after oral administration and maximum plasma concentrations are reached after 1--3 h \[[@CR46]\]. Prednisolone and prednisone are metabolically interconvertible and are present in plasma in a 10:1 ratio, respectively. Because of the rapid metabolism of prednisone to prednisolone, prednisone bioavailability is generally measured in terms of plasma levels of prednisolone and is approximately 70% \[[@CR47]\]. Direct administration of prednisolone bypasses the conversion of prednisone to prednisolone in the liver and is favorable in patients with liver diseases. Only the unbound fraction of prednisolone is biologically active by diffusing into target tissues and cells, and is clinically most relevant \[[@CR48]\]. Pharmacokinetic parameters of corticosteroids are listed in Table [2](#Tab2){ref-type="table"}.Table 2Pharmacokinetic parameters of corticosteroids (adapted from Quetglas et al. \[[@CR22]\])DrugF (%)T~max~ (h)Vd (L/kg)Cl (ml/min/kg)Half-life (h)Prednisolone\
(after prednisone)801--30.4--0.72.5--3.51--3Prednisolone78--851--31.5--2.22.5--3.52--4Methylprednisolone--0.5--11.34--4.92.5--3.5Budesonide10--21--5.9 \[22R\]\
3.4 \[22S\]27.9 \[22R\]\
15.9 \[22S\]2.7*Cl* clearance, *F* bioavailability, *Tmax* time to reach maximum concentration, *Vd* volume of distribution

Dose-dependent pharmacokinetics have been demonstrated for prednisolone \[[@CR48]\]. Both clearance and volume of distribution have been shown to increase with increasing prednisolone concentrations. This dose-dependent clearance of prednisolone might be explained by its concentration-dependent binding to the plasma proteins albumin (low affinity) and transcortin (high affinity) \[[@CR49], [@CR50]\]. Higher doses of prednisone saturate the binding to transcortin, and proportionally more unbound prednisolone will be present, resulting in an increased total clearance. For IBD patients, protein binding is decreased in patients with active disease compared with remission, probably due to decreased plasma albumin concentrations in active disease \[[@CR51]\].

Budesonide is a locally acting corticosteroid with considerable presystemic elimination. It has a low systemic bioavailability (10%) and thereby exhibits lower systemic toxicity compared with prednisone \[[@CR19], [@CR52]--[@CR56]\]. Budesonide has shown to be efficacious and safe in the treatment of UC \[[@CR49]--[@CR51]\]. It is metabolized in the liver via the cytochrome P450 (CYP) 3A4 system into two pharmacologically inactive metabolites, which are primarily excreted via the kidneys \[[@CR52], [@CR53]\]. Since the standard formulation of budesonide is completely absorbed in the gastrointestinal tract, controlled-release formulations for oral intake have been developed. Rectal administration of budesonide has also been demonstrated to be an effective therapeutic option in patients with distal UC \[[@CR54], [@CR55]\]. Strong CYP3A4 inhibitors, such as ketoconazole, will inhibit the metabolism of budesonide, thereby increasing the area under the curve (AUC) of budesonide \[[@CR56]\].

High remission rates and a low number needed to treat have been reported for IBD patients receiving corticosteroids. Nevertheless, approximately 30% of IBD patients have a poor or absent clinical response to corticosteroids \[[@CR57]\]. Abnormalities of the glucocorticoid receptor might be the cause of an absent response to corticosteroids. Low affinity of the glucocorticoid receptor for corticosteroids has been shown in a small prospective trial with UC patients who did not respond to intravenous corticosteroid therapy \[[@CR58]\]. The cause of this low affinity could not be defined, but accelerated intracellular catabolism of the corticosteroid could result in a decrease in binding between the corticosteroid and the glucocorticoid receptor \[[@CR58]\]. Second, this low affinity may be caused by the existence of polymorphisms of the glucocorticoid receptor. However, the association between polymorphisms involving the glucocorticoid receptor and response to corticosteroid treatment in UC patients has not yet been demonstrated \[[@CR57], [@CR59]\]. Additionally, in corticosteroid-naive IBD patients, Schottelius et al. showed an increased expression of the glucocorticoid receptor and a decreased affinity to this receptor compared with a healthy control group \[[@CR60]\]. Deregulation of the glucocorticoid receptor might therefore be of influence on response to corticosteroid treatment in UC patients, but the exact mechanism remains to be elucidated.

Thiopurines {#Sec7}
===========

Thiopurines were traditionally used for the treatment of acute leukaemia \[[@CR61]\], however their use has now become quite common for the treatment of UC, despite relatively limited clinical trial evidence. Thiopurines are slow-acting drugs, taking up to 6 months to reach a therapeutic effect in these patients. Hence, thiopurines cannot be used as induction therapy. In active UC, treatment with thiopurines has been effective in combination with corticosteroid induction because of the delayed therapeutic effect \[[@CR5]\]. Thiopurines can also be used in combination with anti-TNF agents to induce and maintain remission \[[@CR62]\]. For corticosteroid-dependent UC, azathioprine (AZA) was more effective than 5-ASA in achieving clinical and endoscopic remission \[[@CR63], [@CR64]\].

Pharmacokinetic and Pharmacodynamic Considerations {#Sec8}
--------------------------------------------------

Thiopurines include the orally administered prodrugs AZA, mercaptopurine (MP), and thioguanine (TG). TG is considered to be an unconventional thiopurine that is only being used in a few countries when patients do not respond to AZA or MP due to inefficacy or side effects.

After absorption, glutathione S-transferase converts 90% of AZA to 6-mercaptopurine (6-MP) in erythrocytes \[[@CR65], [@CR66]\]. The metabolism of AZA is shown in Fig. [2](#Fig2){ref-type="fig"}. 6-MP is metabolized by one of three different enzymes. Xanthine oxidase (XO) and thiopurine S-methyltransferase (TPMT) are catabolic enzymes leading to the inactive metabolites 6-thiouric acid (6-TUA) and 6-methylmercaptopurine (6-MMP), respectively \[[@CR67]\]. The metabolite 6-MMP has been related to thiopurine-induced liver toxicity \[[@CR68]\]. Metabolism of 6-MP by the anabolic enzyme hypoxanthine--guanine phosphoribosyltransferase (HPRT) eventually leads to the pharmacologically active 6-thioguanine nucleotide (6-TGN) \[[@CR69]\]. The low bioavailability (5--37%) of 6-MP is a result of the high first-pass effect caused by the rapid and extensive metabolism of XO into inactive metabolites \[[@CR70]\]. The metabolism of 6-TG differs from AZA and 6-MP because 6-TG is metabolized by HPRT directly into 6-TGN, whereas 6-MP nucleotide is oxidized in a rate-limiting step to thioxanthine nucleotide prior to 6-TGN formation \[[@CR71]\]. In summary, 6-TGN is responsible for the therapeutic effect, whereas 6-MMP causes hepatotoxicity. Pharmacokinetic parameters of 6-MP are listed in Table [3](#Tab3){ref-type="table"}.Fig. 2Thiopurine metabolism. *6*-*TG* thioguanine, *6*-*TGN* 6-thioguanine nucleotide, *6*-*MMP* 6-methylmercaptopurine, *6*-*MP* 6-mercaptopurine, *6*-*TIMP* 6-thioinosine monophosphate, *6*-*TUA* 6-thiouric acid, *GST* glutathione S-transferase, *HPRT* hypoxanthine--guanine phosphoribosyltransferase, *IMPDH* inosine 5-monophosphate dehydrogenase, *TPMT* thiopurine S-methyltransferase, *XO* xanthine oxidaseTable 3Pharmacokinetic parameters of 6-mercaptopurineDrugDosePopulationC~max~ (ng/ml)T~max~ (h)CL (L/h)^a^Vss (L)^a^Half-life (h)F (%)AUC (ng/h/ml)6-mercaptopurine \[[@CR220]\]50 mg PO single-dose AZAHealthy16.9 \[8.3--41.8\]2 \[[@CR1]--[@CR3]\]------47.4 \[[@CR27]--[@CR83]\]41.6 \[32.5--98.8\]6-mercaptopurine \[[@CR220]\]50 mg IV single-dose AZAHealthy----231 \[168--469\]392 \[273--1085\]1.1 \[0.8--2.6\]--109.6 \[45.6--162.1\]6-mercaptopurine \[[@CR220]\]50 mg DRO single-dose AZAHealthy3.7 \[2.5 -- 12.6\]5 \[[@CR5], [@CR6]\]------7.1 \[0--38.7\]9.6 \[0--21.8\]Data are expressed as median \[range\]^a^For a 70 kg patient*AUC* area under the curve, *AZA* azathioprine, *Cl* clearance, *C*~*max*~ maximum concentration, *DRO* delayed-release oral, *F* bioavailability, *IV* intravenously, *PO* orally, *T*~*max*~ time to reach maximum concentration, *Vss* volume of distribution at steady state

After administration of AZA and MP, TPMT competes with XO and HPRT, thereby determining the amount of 6-TGN metabolites that are formed. The gene coding for TPMT exhibits polymorphism, which causes high interpatient variability in exposure to 6-TGN. There are several known genetic polymorphisms related to decreased TMPT activity, and thereby increased 6-TGN concentrations, resulting in side effects \[[@CR72]\]. A meta-analysis by Liu et al. showed an association between TPMT polymorphisms, thiopurine-induced overall side effects and bone marrow toxicity \[[@CR73]\].

The mechanism of action of thiopurines is still not clear and it is therefore not entirely known why thiopurines are slow-acting. Incorporation of 6-TGN as false purine analogues into DNA and RNA is responsible for the cytotoxic and immunosuppressive effects of thiopurines. After incorporation, DNA damage, cell-cycle arrest and apoptosis occur, resulting in the inhibition of nucleotide and protein synthesis, leading to inhibition of inflammatory gene expression \[[@CR69]\]. Apoptosis induction requires co-stimulation with CD28, which is mediated by specific blockade of Rac1 activation through binding of AZA-generated 6-thioguanine triphosphate (6-Thio-GTP) to Rac1 instead of GTP \[[@CR3]\]. This mechanism of action might explain a delay in clinical efficacy.

6-TGN concentrations are measured in erythrocytes by the Lennard or Dervieux--Boulieu chromatographic method \[[@CR74]\]. Since measurement of 6-TGN concentrations results in 2.6-fold higher levels when measured by the Dervieux--Boulieu method compared with the Lennard method, the type of assay used should be taken into account when interpreting 6-TGN concentrations. Higher 6-TGN levels have been associated with clinical response and remission in IBD patients \[[@CR68], [@CR75]\]. 6-TGN concentrations, measured by the Lennard method, of \> 230 pmol/8 × 10^8^ have been related to better clinical outcomes in terms of clinical response rates, and 6-TGN concentrations \> 450 pmol/8 × 10^8^ are associated with myelotoxicity \[[@CR68], [@CR76], [@CR77]\]. Allopurinol influences the pharmacokinetics of thiopurines by increasing production of 6-TGN. Allopurinol inhibits XO and shunts the metabolic pathway of thiopurines towards the production of 6-TGN \[[@CR78]\]. The original dose of thiopurine should then be reduced by at least 50% to prevent toxic 6-TGN concentrations. Likewise, combination treatment with 5-ASA can be considered in order to increase 6-TGN concentrations. The metabolic pathway of thiopurine shifts with the addition of 5-ASA, and 6-TGN concentrations consequently increase \[[@CR79]--[@CR82]\].

A population pharmacokinetic model has been published for pediatric patients with acute lymphoblastic leukaemia treated with 6-MP \[[@CR83]\] that showed large interpatient variability in the clearance of pharmacologically active 6-TGN and toxic 6-MMP metabolites. In the population pharmacokinetic model, TMPT genotype was shown to influence the metabolic transformation rate of 6-MP into 6-TGN. This suggests that pharmacogenetically guided dosing of thiopurines is beneficial in optimizing individual treatment. To our knowledge, no population pharmacokinetic models are currently available describing pharmacokinetics of thiopurines in UC patients.

TDM has shown to be useful during treatment with thiopurines because of the small therapeutic range of 6-TGN concentrations balancing between therapeutic concentrations and toxicity \[[@CR84]\]. Patients reach steady-state after approximately 4 weeks, therefore TDM within the first 4 weeks is not useful, except when a patient's nonadherence is suspected. Next to measurement of 6-TGN concentrations, toxic 6-MMP concentrations can be useful when using TDM.

When applying TDM in nonresponders, patients with normal 6-TGN levels are likely refractory to treatment with thiopurines. Patients with low concentrations of both 6-TGN and 6-MMP are most likely underdosed or not compliant. Patients with low 6-TGN levels and high 6-MMP levels are suggested to be metabolically shunting away from 6-TGN production, where more TMPT converts 6-MP to the toxic 6-MMP compared with less 6-MP that is converted to the active 6-TGN by HPRT \[[@CR85]\]. The addition of allopurinol can have added value in these patients with a skewed metabolic pathway. An overview of applying TDM in nonresponders is given in Fig. [3](#Fig3){ref-type="fig"}. After 4 weeks, steady state is again reached and 6-TGN and 6-MMP concentrations should be re-analysed.Fig. 3Therapeutic drug monitoring strategy for thiopurines. *6*-*TGN* 6-thioguanine nucleotide, *6*-*MMP* 6-methylmercaptopurine

TPMT genotyping could be considered before starting therapy to identify patients at risk for developing bone marrow toxicity related to 6-MP use \[[@CR68], [@CR86], [@CR87]\]. However, there is no consensus regarding the merit of genotyping for TPMT deficiency and related myelotoxicity since TPMT genotype is not the only cause of myelotoxicity \[[@CR72], [@CR88]\].

Calcineurin Inhibitors {#Sec9}
======================

Ciclosporin A (CsA) binds to calcineurin, an enzyme involved in signal transduction of T-lymphocytes and expression of the proinflammatory IL-2 \[[@CR89]\]. Tacrolimus is another calcineurin inhibitor that is currently used for the prevention of transplant rejection. Tacrolimus in complex with immunophilin binds to calcineurin, thereby inhibiting phosphatase activity. Inhibition of phosphatase activity results in reduced cytokine production, in particular IL-2, which results in suppressed T-cell proliferation \[[@CR90]\]. The introduction of CsA as an immunosuppressive drug after organ (e.g. liver, kidney, lung) transplantation dramatically changed survival rates for this patient population. Intravenously administered CsA has also shown to be beneficial in patients with severe UC \[[@CR91]--[@CR93]\]. Monotherapy with CsA can be a short-term alternative in patients with acute severe UC, refractory to corticosteroids, when a rapid onset is preferred as a bridge to thiopurines or vedolizumab \[[@CR5]\]. Oral tacrolimus has proven to be safe and effective as remission-induction therapy for patients with steroid refractory UC \[[@CR94], [@CR95]\]. In clinical practice, oral tacrolimus is used as both remission-induction and maintenance therapy in UC patients. Tacrolimus is a more potent immunosuppressant than CsA, and, in contrast to CsA, which is only administered intravenously, tacrolimus can be administered orally, usually twice daily.

Pharmacokinetic and Pharmacodynamic Considerations {#Sec10}
--------------------------------------------------

CsA and tacrolimus are highly lipophilic compounds with limited solubility. Absorption mainly occurs in the small intestine \[[@CR96]--[@CR99]\]. For tacrolimus, a bioavailability of 20--25% has been reported \[[@CR98], [@CR99]\]. For CsA, bioavailability ranged widely, with values from 11.4 to 87.4% in renal transplant patients \[[@CR100]\]. Although most pharmacokinetic studies with CsA have been performed in transplant patients, the pharmacokinetics of CsA have also been studied in 12 patients with Crohn's disease (CD) after single intravenous and oral administration \[[@CR101]\]. This study reported a lower median bioavailability (23.7%) than the average value estimated from a large transplant patient population (30%) \[[@CR102]\]. After oral administration of a single dose of CsA in five healthy subjects, a low mean bioavailability was also reported (18%) \[[@CR103]\]. Pharmacokinetic parameters of CsA and tacrolimus are listed in Table [4](#Tab4){ref-type="table"}. The influence of food on the bioavailability of CsA has been under discussion, but intake of a high-fat breakfast increased the bioavailability of CsA in healthy volunteers compared with fasting \[[@CR104]\]. With the introduction of a microemulsion formula (Neoral^®^), variability in absorption of CsA could be reduced, and this formula provided a more predictable and consistent concentration--time profile \[[@CR105], [@CR106]\]. In an open randomized study with 48 healthy volunteers, the relative bioavailability of the microemulsion formula of CsA compared with the commercial formula ranged from 174 to 239% \[[@CR107]\]. For the IBD patient population, the pharmacokinetic parameters of CsA microemulsion were similar to healthy volunteers and other patient populations treated with CsA microemulsion \[[@CR108]\].Table 4Pharmacokinetic parameters of calcineurin inhibitorsDrugDosePopulationC~max~ (ng/ml)T~max~ (min)CL (L/min)Vd (L/kg)Half-life (min)F (%)AUC (µg\*h/L)Ciclosporin microemulsion \[[@CR108]\]200 mg PO daily^a^IBD782^b^78^b^----144^b^----Ciclosporin \[[@CR221]\]3.5 mg/kg IV^c^Renal transplant----0.31 (0.1)2.88 (1.1)768 (228)----Ciclosporin \[[@CR221]\]618 (165) mg single-dose PORenal transplant860 (286)174 (60)------27 (13)8045 (2497)Ciclosporin \[[@CR103]\]5 mg/kg single-dose IVHealthy5520 (1101)102 (24)0.203 (0.049)^d^--366 (132)10030,827 (8814)Ciclosporin \[[@CR103]\]5 mg/kg single-dose POHealthy800 (299)102 (24)----360 (216)185071 (1706)Ciclosporin \[[@CR222]\]3 mg/kg single-dose POCD360 (0--818)^e^120 (60--480)^e^------23.7 (0.0--49.1)^e^2218 (1549--3441)^e^Tacrolimus \[[@CR111]\]5 mg single-dose\
POHealthy29.7960.05^d^1.942088--243Tacrolimus \[[@CR111]\]0.2 mg/kg/day POKidney transplant recipients19.2180--------203Tacrolimus \[[@CR111]\]0.3 mg/kg/day POLiver transplant recipients68.5138--------519Data are expressed as mean (standard deviation) unless otherwise stated^a^After 7 days of treatment^b^Estimated value^c^After 3 days of treatment^d^Based on a 70 kg patient^e^Median (range)*AUC* area under the curve, *CD* Crohn's disease, *Cl* clearance, *C*~*max*~ maximum concentration, *F* bioavailability, *IBD* inflammatory bowel disease, *IV* intravenously, *PO* orally, *T*~*max*~ time to reach maximum concentration, *Vd* volume of distribution

After absorption, CsA and tacrolimus are metabolized in the liver and small intestine by CYP3A enzymes. Both compounds are substrates for P-glycoprotein (P-gp) \[[@CR109]--[@CR114]\]. In the gut, P-gp, also known as multidrug-resistant protein 1, functions as a biological barrier transporting toxins and xenobiotics out of the cell \[[@CR115]\]. The predominant metabolite of tacrolimus is 13-*O*-demethyl-tacrolimus, which has immunosuppressive activity \[[@CR112]\]. Up to 95% of tacrolimus is excreted predominantly into faeces as metabolites, and a negligible amount of unchanged drug can be found in both urine and faeces \[[@CR116]\]. CsA is primarily excreted into the bile \[[@CR117]\].

Drugs metabolized via the CYP3A metabolic pathway interfere with CsA and tacrolimus metabolism, which can result in altered blood concentrations. Genetic polymorphism of CYP3A genes could potentially explain the widely ranging inter- and intravariability in absorption and clearance of CsA. However, a relationship between CYP3A4 polymorphism and required dose adjustments has not been found \[[@CR118]--[@CR121]\]. Polymorphism in ABCB1, the gene encoding for P-gp, and CYP3A5 polymorphism have been suggested to affect the pharmacokinetics of tacrolimus in UC patients \[[@CR122], [@CR123]\]. In Asian UC patients, CYP3A5\*1 polymorphism (CYP3A5 'expression') has been associated with lower tacrolimus trough concentrations and lower clinical remission rates at week 4 compared with patients without CYP3A5\*1 \[[@CR122]\]. In 89 IBD (mostly UC) patients treated with tacrolimus, the influence of polymorphism in both CYP3A5 and ABCB1 were studied \[[@CR123]\]. Variants in ABCB1 polymorphism, particular at position 3435 (ABCB1 3435C\>T), showed an association with short-term clinical remission. Genotyping for tacrolimus can be of interest to individualize tacrolimus therapy, but implementation in clinical practice would be costly and would likely not affect the decision to start tacrolimus.

Because of the large interindividual variability and narrow therapeutic range, TDM for CsA has great potential for improving clinical outcomes and has been extensively described for patients after renal transplantation. Trough samples were originally taken as a surrogate for exposure (AUC) to reduce toxicity in these patients. However, CsA samples at trough did not predict rejection-free survival and was therefore considered as a suboptimal clinical predictor. Subsequent studies identified AUC for the first 12 h (AUC~12~) as a more sensitive predictor. Because monitoring of AUC~12~ is rather impractical, CsA concentrations 2 h after administration are considered best to use when applying TDM in transplant patients \[[@CR124]--[@CR129]\]. Although CsA concentrations 2 h after administration are measured in renal transplant patients, in patients with an UC exacerbation it is recommended to measure trough concentrations at days 2 and 4 after the start of CsA. For intravenous and orally administered CsA, trough concentrations between 250 and 450 ng/ml, and 150 and 250 ng/ml, are aimed for, respectively. For IBD patients with a dose of 4 mg/kg/day, steady-state trough concentrations were between 300 and 400 ng/ml \[[@CR130]\]. UC patients receiving a dose of 2 mg/kg and achieving trough concentrations between 150 and 250 ng/ml have shown similar efficacy and less adverse events \[[@CR131], [@CR132]\].

The extensive binding of tacrolimus to erythrocytes is saturable, and hence concentration-dependent. The blood--plasma ratio for tacrolimus ranges from 15:1 to 35:1, and can vary even more depending on drug concentration and haematocrit values \[[@CR98], [@CR111], [@CR133], [@CR134]\]. The blood--plasma ratio will decrease with higher drug concentrations and lower haematocrit values. Because tacrolimus binds extensively to erythrocytes, drug levels are routinely being measured in whole blood \[[@CR99]\]. In plasma, tacrolimus binds to α1-acid glycoprotein and albumin with high affinity; its unbound fraction is \< 1%. Unbound tacrolimus is thought to mediate the pharmacological effects \[[@CR133]--[@CR135]\]. In a randomized, placebo-controlled, dose-finding study, corticosteroid-refractory active UC patients received placebo or oral tacrolimus administered twice daily over a 2-week period, followed by an open-label 10-week extension \[[@CR94]\]. Based on tacrolimus whole blood trough levels, patients were assigned to either a high (10--15 ng/ml) or low (5--10 ng/ml) trough concentration group. The clinical response rate (improvement in disease activity index score ≥ 4 points, all categories improved) at 2 weeks was higher in patients with the high troughs compared with low troughs (68.4 vs. 38.1%, respectively). Consequently, in daily practice, the target range of tacrolimus trough levels ranges from 10 to 15 ng/ml, since this range is associated with improved clinical outcomes in UC. Blood trough levels of tacrolimus can be affected by fasting, and absorption of tacrolimus decreases by the presence of food \[[@CR136], [@CR137]\]. The maximum concentration (*C*~max~) after oral administration is up to fourfold higher during fasting compared with a fed condition.

Biologicals {#Sec11}
===========

Anti-Tumor Necrosis Factor Agents {#Sec12}
---------------------------------

According to the classic therapeutic step-up approach, use of monoclonal antibodies (mAbs) is considered to be the last medical treatment option before surgery. However, in severe UC, IFX can also offer an early treatment option. MAbs targeting TNF cover the majority of the registered therapeutic mAbs used in the treatment of UC. Approved therapeutic mAbs for UC are of the immunoglobulin (Ig) G1 antibody type consisting of a Fab fragment and a Fc-portion. IFX, an intravenously administered chimeric IgG1 antibody, was the first anti-TNF agent approved for the treatment of UC. Adalimumab (ADL) and golimumab (GLM) are both fully human, subcutaneously administered IgG1 antibodies registered for the treatment of UC. These agents are effective as induction as well as maintenance treatment in UC \[[@CR138]--[@CR142]\]. A meta-analysis conducted by Thorlund et al. showed superiority compared with placebo for all three anti-TNF agents in terms of achieving clinical response and remission after 6--8 weeks \[[@CR143]\]. Additionally, a more recent meta-analysis showed that anti-TNF agents were more effective than placebo for both inducing (45 vs. 30%) and maintaining mucosal healing (33 vs. 18%) \[[@CR144]\].

### Pharmacokinetic and Pharmacodynamic Considerations {#Sec13}

Therapeutic mAbs are administered parenterally since oral administration of mAbs is challenged by their high molecular weight (approximately 150 kDa), hydrophilicity, and gastric degradation. Despite these drawbacks, a novel oral anti-TNF mAb is under development and has proven efficacy in both IBD mouse models and a first-in-human trial in UC patients \[[@CR145], [@CR146]\]. Intravenous administration of a mAb provides instantaneously high systemic concentrations, which is beneficial in severe UC. After subcutaneous administration of the mAb, absorption takes place via lymphatic drainage, and the *C*~max~ is reached after several days \[[@CR147]\]. Systemic absorption and presystemic catabolism of subcutaneously administered mAbs determine their bioavailability \[[@CR147]\]. Reported bioavailabilities for ADL after subcutaneous administration range from 50 to 100%, and a bioavailability of 51% is reported for GLM \[[@CR147], [@CR148]\]. Additionally, no differences were found in bioavailability after administration of GLM in the upper arm, thigh or abdomen \[[@CR148]\]. Pharmacokinetic parameters of IFX, ADL, and GLM are listed in Table [5](#Tab5){ref-type="table"}. Because of their high molecular weight and hydrophilicity, there is limited distribution of mAbs into peripheral tissue. A volume of distribution of 4.5--6 L has been reported for IFX at steady state, approximately equal to the extracellular fluid volume \[[@CR149]\]. The exact mechanisms by which mAbs are eliminated from the body are not fully understood, but the primary route is via proteolytic catabolism after receptor-mediated endocytosis in the reticuloendothelial system (RES). Additionally, loss of IFX into stool has been demonstrated in patients with moderate to severely active UC, with highest faecal IFX concentrations found in patients with primary nonresponse \[[@CR150]\]. Elimination via the faeces has not yet been demonstrated for other biologicals.Table 5Pharmacokinetic parameters of anti-tumour necrosis factor agentsDrugDosePopulationC~max~ (µg/ml)T~max~ (days)Half-life (days)CL (L/day)Vd (L)AUC (µg\*h/ml)F (%)Infliximab \[[@CR223]\]^a^--IBD----13.7 \[12.4--15.3\]^b^0.015 \[0.013--0.016\]^b^------Infliximab \[[@CR224]\]5 mg/kg single infusionHealthy126.2 (17.9)^c^0.0875 \[0.083--0.254\]^b^14.1 (6.5)^c^0.26 (0.072)^c^4.8 (1.3)^c^37,022 (9398)^c^--Infliximab \[[@CR225]\]5 mg/kg single infusionCD75^d^7.8^d^0.44^d,e^5.6^d,e^----Infliximab \[[@CR226]\]5 mg/kg single infusionCD118^d^--9.5^d^0.24^d^------Adalimumab \[[@CR227]\]40 mg SC single doseHealthy4.53 (1.15)^c^8.0 \[2.5--15\]^b^16.8 \[3.3--218\]^b^0.33 (0.17)^c^7.53 (4.04)^c^2996.2 (1106.9)^c^--Adalimumab \[[@CR228]\]40 mg SC single doseHealthy3.6 (1.1)^f^8.0 \[[@CR2]--[@CR21]\]^b^14.5 (7.5)^f^0.38 (0.016)^f^7.87 (2.47)^f^2167.38 (979.66)^f^--Adalimumab \[[@CR229]\]40 mg SC single doseHealthy4.7 (1.6)^c^5.5 (2.3)^c^--------64Golimumab \[[@CR230]\]SC/IVPsA/RA3.2 (1.4)^c^2--6ca. 140.34--0.47^e^4.1--8.8 ^g^--53Golimumab \[[@CR231]\]100 mg SC single doseRA4.6 \[0.5--12.1\]^b^3.5 \[2.0--7.1\]^b^12.5 \[2.9--25.3\]^b,h^1.2 \[0.43--3.1\]^b,h^19.9 \[6.7--71\]^b,h^--53^a^Includes six studies^b^Median \[range\]^c^Mean (standard deviation)^d^Median^e^Based on bodyweight of 70 kg^f^Mean (CV %)^g^After single IV administration over the dose range of 0.1--10.0 mg/kg^h^Determined after 20 weeks of continuous treatment*AUC* area under the curve, *CD* Crohn's disease, *Cl* clearance, *C*~*max*~ maximum concentration, *CV* coefficient of variation, *F* bioavailability, *IBD* inflammatory bowel disease, *IV* intravenously, *PsA* psoriatic arthritis, *RA* rheumatoid arthritis, *SC* subcutaneously, *T*~*max*~ time to reach maximum concentration, *Vd* volume of distribution

IgG1 mAbs interact with the neonatal Fc receptor (FcRn), thereby increasing their half-life (Fig. [4](#Fig4){ref-type="fig"}). FcRn is functionally expressed in monocytes, macrophages, dendritic cells, and endothelial cells \[[@CR151], [@CR152]\]. After endocytosis into vascular endothelial cells, FcRn binds the IgG antibody within the acidic environment of the endosome. Binding to FcRn results in protection from degradation, thereby prolonging half-life. The IgG antibody is returned to the cell surface and dissociates from FcRn in a physiologic environment (pH 7.4) and is released into the systemic circulation.Fig. 4FcRn recycling mechanism. *IgG* immunoglobulin G, *FcRn* neonatal Fc receptor

In patients with active IBD, increased levels of TNF have been found in blood, epithelial tissue and stool \[[@CR153], [@CR154]\]. TNF is a pro-inflammatory cytokine that is produced by macrophages and monocytes \[[@CR155]\]. TNF is a trimer and appears as both soluble (sTNF)- and membrane (mTNF)-bound TNF. IFX binds to both trimeric and monomeric forms of TNF; the latter may prevent association of these subunits to form the bioactive trimeric TNF \[[@CR156]\]. TNF is produced as mTNF, from which sTNF is released by proteolytic cleavage \[[@CR157]\]. Both sTNF and mTNF production is increased in patients with IBD, and both forms play a role in driving intestinal inflammation \[[@CR157]\]. Binding of sTNF to type 1 (TNF-R1) and type 2 TNF receptors (TNF-R2) mediates multiple biologic effects. Binding to TNF-R1 leads to apoptosis and NF-κB activation and translocation to the nucleus. TNF-R2 has a role in circulating blood leukocytes and can lead to NF-κB signalling \[[@CR158], [@CR159]\]. mTNF also binds to TNF-R1 and TNF-R2, but its biological activity is probably assigned to binding to TNF-R2 \[[@CR160]\]. Both TNF-R1 and TNF-R2 are cell surface receptors and are expressed on almost all nucleated cells \[[@CR161]\]. Polymorphisms in genes encoding TNF receptors have been studied, and Pierik et al. found that the TNFR2 587G allele was more frequently present in UC. However, the TNF receptor polymorphisms did not predict clinical response to IFX treatment \[[@CR159]\].

Higher serum trough concentrations of anti-TNF agents during maintenance treatment are associated with improved clinical outcomes (i.e. clinical response, clinical remission and mucosal healing) in UC patients. In contrast, low(er) concentrations have been demonstrated to be associated with the formation of antidrug antibodies (ADAs). Serum trough IFX concentrations at steady-state between 3 and 7 µg/ml have been related to improved clinical outcomes \[[@CR9], [@CR138], [@CR162]--[@CR170]\].

For ADL, serum trough concentrations \> 7.1 µg/ml are associated with mucosal healing, with the increased rate of mucosal healing reaching a plateau at 12 µg/ml in IBD patients \[[@CR171]\]. For GLM, less data are available with regard to optimal serum trough concentrations. To date, there is no consensus about what the therapeutic range of GLM should be. Detrez et al. performed a prospective trial to define the therapeutic range of GLM in UC patients. A cut-off value of 2.6 µg/ml at week 6 was associated with partial clinical response at 14 weeks (defined as clinical improvement despite persistent rectal blood loss) \[[@CR172]\].

Although efficacy for anti-TNF agents has been proven, up to 30% of patients have no clinical improvement after initiation of anti-TNF therapy (primary nonresponse), and up to 50% of patients lose response over time (secondary nonresponse) \[[@CR173]\]. TDM may therefore be applied in order to prevent primary and secondary nonresponse \[[@CR11], [@CR174]--[@CR177]\]. To understand the mechanisms behind the phenomenon of primary and secondary nonresponse, understanding of factors that influence the pharmacokinetics and pharmacodynamics of mAbs is most important. Population pharmacokinetic modeling has provided insight into factors associated with the clearance of mAbs by identifying variability between and within patients.

For IFX, several population pharmacokinetic analyses have been performed to identify and quantify important patient characteristics influencing the pharmacokinetics in UC patients. First, the relationship between the presence of antibodies against IFX and an increased clearance of IFX in patients with UC has repeatedly been shown \[[@CR178]--[@CR180]\]. Second, baseline serum albumin concentrations have been found to be inversely and strongly related to clearance \[[@CR178]\]. Like IFX, albumin also interacts with FcRn, thereby prolonging half-life (Fig. [4](#Fig4){ref-type="fig"}). Lower albumin concentrations, representing a more severe disease status, could reflect a lower number of FcRns, thereby explaining an increased clearance of IFX. This inverse relationship has also been reported by Buurman et al. \[[@CR180]\]. However, due to the low variability in albumin levels of patients included in that study, this effect was not large enough to be incorporated into their final population pharmacokinetic model.

Third, body weight has been identified as a covariate influencing volume of distribution \[[@CR178], [@CR179]\]. Since volume of distribution of IFX is similar to the extracellular fluid volume, and this increases with body weight, the effect of body weight on volume of distribution is expected. This shows the need for weight-based dosing of IFX in order to allow equivalent exposure to IFX among patients with different body weights.

Elevated C-reactive protein (CRP), as a marker of disease activity, has been associated with lower IFX trough concentrations and loss of response to IFX in IBD patients \[[@CR181], [@CR182]\]. For patients with rheumatoid arthritis, higher baseline CRP has been associated with an increased clearance; however, CRP is not always elevated in patients with mild to moderately active UC \[[@CR183]\]. This might explain why CRP is often not recognized as a significant covariate associated with increased clearance of IFX in UC patients. In addition, albumin might already explain most of the variability seen in the clearance of IFX due to disease activity.

For ADL, no population pharmacokinetic analyses have been performed to identify factors influencing pharmacokinetics in UC patients. Nevertheless, Ternant et al. were the first to report a quantitative description of the pharmacokinetics of ADL in patients with CD \[[@CR184]\], and showed a 5.5-fold increase in clearance in the presence of antibodies to ADL. Sharma et al. also identified the influence of antibodies to ADL, and additionally reported body weight as a significant covariate influencing both clearance and volume of distribution in a paediatric CD patient population treated with ADL \[[@CR185]\].

To identify factors influencing the pharmacokinetics of GLM, a post hoc analysis of the PURSUIT trial was performed \[[@CR186]\]. Body weight, serum albumin and antibodies against GLM were found as influencing factors on the pharmacokinetics of GLM.

The presence of ADAs can be persistent or transient (i.e. transient ADAs disappear over time) and neutralizing or non-neutralizing \[[@CR163], [@CR187], [@CR188]\]. Neutralizing ADAs directly prevent an anti-TNF agent from binding TNF by binding to the TNF-binding fragment (Fab) of the anti-TNF agent or by steric hindrance. Non-neutralizing ADAs also form a complex with anti-TNF agents, but do not prevent binding of the anti-TNF agent to TNF; however, the pharmacokinetics of the anti-TNF agents might still be altered \[[@CR188]\]. Different assays can be used to assess the ADA status of a patient. Most assays cannot distinguish between neutralizing and non-neutralizing ADAs, and quantitative results cannot be compared between different assays or different drugs. Most of these assays are not drug tolerant and are therefore not able to detect ADAs in the presence of the drug \[[@CR189]\]; however, drug-tolerant assays are able to detect antibodies in the presence of the drug \[[@CR190]\]. A recent paper by Van Stappen et al. evaluated the clinical relevance of a drug-tolerant assay \[[@CR191]\], and concluded that a drug-tolerant assay allows closer follow-up of the effect of dose intensification on ADA concentrations and the differentiation between transient and persistent ADAs. However, no clinical benefit was shown for the use of a drug-tolerant assay during maintenance treatment with IFX.

Next to ADA formation, concomitant treatment with immunomodulators, such as thiopurines or methotrexate (MTX), can also influence the pharmacokinetics of anti-TNF mAbs \[[@CR192], [@CR193]\]. Higher IFX trough concentrations have been found in IBD patients receiving both IFX and concomitant immunomodulator treatment compared with the IFX monotherapy group (7.5 vs. 4.6 µg/ml, *p* = 0.04) \[[@CR194]\]. The addition of an immunomodulator to IBD patients receiving anti-TNF monotherapy, with loss of response due to immunogenicity, has been shown to result in undetectable ADAs, increased serum drug concentrations and regained clinical response \[[@CR193]\]. In addition, the UC SUCCESS trial showed significantly higher rates of corticosteroid-free remission (39.7 vs. 22.1%) and mucosal healing (62.8 vs. 54.6%) at week 16 in UC patients receiving IFX/AZA combination therapy compared with patients receiving IFX alone \[[@CR62]\]. In clinical practice, the initiation of anti-TNF therapy should be combined with an immunomodulator to prevent the formation of detectable ADAs.

Only a part of the interpatient variability of clearance of anti-TNF agents is explained by body weight, ADAs and disease activity (albumin). Unexplained interpatient variability may be reduced by TDM. Dashboard systems (software packages that integrate information from multiple components into a single display for clinical use) are currently being developed to implement adaptive dosing strategies \[[@CR195]\]. Dashboard systems for clinical decision support use Bayesian approaches in which a priori information is combined with a posteriori information to predict future concentrations \[[@CR196]\]. A recent paper by Wojciechowski et al. showed the potential benefits of model-based dosing for IFX \[[@CR197]\]. They compared several dosing strategies by simulating a virtual population with time-varying covariates. This in silico assessment showed that model-based approaches were superior to other strategies (label recommendations, TDM-guided stepwise dosing, TDM-guided proportional dosing). The application of model-based dosing during the maintenance phase resulted in more patients reaching target trough concentrations, and additionally decreased interpatient variability in IFX serum concentrations; however, this should be confirmed by a large prospective trial.

The randomized controlled TAXIT trial included 263 adult IBD patients with stable response to maintenance IFX therapy \[[@CR198]\]. After dose optimization, patients received either clinically based dosing or concentration-based dosing based on an algorithm. Concentration-based dosing was not superior to clinically-based dosing regarding clinical and biochemical remission after 1 year, but was associated with fewer flares. Recently, the TAILORIX trial has been published comparing concentration-based dosing with adaptive dosing based on symptoms alone \[[@CR199]\]. Anti-TNF-naive CD patients starting on IFX were included, and the percentage of patients with sustained corticosteroid-free clinical remission from weeks 22 through 54 was assessed. Although the study was stated to be underpowered to show the benefit of TDM, it was concluded that concentration-based IFX dosing was not superior to dosing based on symptoms alone. In conclusion, the prospective TAXIT and TAILORIX trials were not able to show the merit of TDM in IFX maintenance treatment; however, when a patient is lacking or losing clinical response to IFX, TDM provides useful information for the clinician. With low serum trough concentrations, the proven concentration--effect relationship for IFX justifies increasing the dose or decreasing the dosing interval in order to (re)gain clinical response. In addition, detectable ADAs can be overcome by the addition of an immunomodulator. When a patient is lacking or losing response and TDM shows sufficiently high serum trough levels of IFX, switching to another therapy should be considered. Potential benefit of TDM during the induction phase remains an interesting concept, but little is known about the optimal therapeutic window for IFX during induction phase. Papamichael et al. showed that IFX trough concentrations of 28.3, 15, and 2.1 µg/ml are associated with short-term mucosal healing at weeks 2, 6, and 14, respectively \[[@CR200]\]. On the contrary, TDM can also be applied for dose de-escalation. Most mAbs do not have a maximum tolerated dose resulting in toxic concentrations, but high-dose IFX may be associated with more serious adverse events requiring hospitalization \[[@CR201]\]. Regarding costs, in CD patients with secondary loss of response to IFX, algorithm-based dosing using serum IFX concentrations was shown to reduce average treatment costs in the long-term and without any negative effect on clinical efficacy \[[@CR202], [@CR203]\].

Vedolizumab {#Sec14}
-----------

The latest addition to the biological treatment armamentarium for UC is vedolizumab, which was registered by the EMA and US FDA in 2014. Vedolizumab is a humanized IgG1 mAb that targets α4ß7-integrine, which is present on T cells in the lamina propria \[[@CR204]\]. Binding of vedolizumab to α4ß7 prevents binding of α4ß7 to mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1), which is expressed on endothelial cells \[[@CR205]\]. Prevention of the α4ß7/MAdCAM-1 interaction blocks the infiltration of α4ß7+ cells into the gastrointestinal mucosa and gut-associated lymphoid tissue, suppressing gut inflammation \[[@CR205], [@CR206]\]. The pivotal GEMINI-1 trial showed efficacy of vedolizumab in UC, with a greater proportion of patients achieving clinical response, clinical remission, and mucosal healing compared with placebo \[[@CR207]\]. Vedolizumab is administered intravenously as a fixed dose of 300 mg at weeks 0, 2 and 6, followed by infusion every 8 weeks during the maintenance phase.

### Pharmacokinetics and Pharmacodynamics {#Sec15}

As an IgG mAb, vedolizumab exhibits the same pharmacokinetic principles as anti-TNF mAbs. The half-life of vedolizumab (25.5 days) is relatively long compared with other therapeutic mAbs \[[@CR149], [@CR208]\]. In theory, it takes four to five times a half-life before a drug reaches steady state and has maximal potential effect. It also takes four to five times the half-life before the drug is fully eliminated from the body after discontinuation of treatment. Pharmacokinetic parameters of vedolizumab are listed in Table [6](#Tab6){ref-type="table"}. Elimination of vedolizumab has been described by parallel linear and nonlinear elimination \[[@CR208]\]. The linear elimination represents a nonsaturable pathway, such as Fc-mediated elimination that occurs at higher therapeutic concentrations. The nonlinear elimination might be the result of clearance by saturable, target-mediated mechanisms such as receptor-mediated endocytosis occurring at lower concentrations. This target-mediated drug disposition has previously been reported for therapeutic mAbs showing affected pharmacokinetics by high-target affinity \[[@CR209], [@CR210]\].Table 6Pharmacokinetic parameters of vedolizumabDrugDosePopulationC~max~ (µg/ml)T~max~ (days)Half-life (days)Cl (L/day)Vd (L)AUC (µg\*day/ml)Vedolizumab \[[@CR232]\]2 mg/kg single-dose IVHealthy58.4 (19.6)--14.1 (2.67)0.164 (10.7)3.28 (19.9)955 (15.2)Vedolizumab \[[@CR232]\]6 mg/kg single-dose IVHealthy150 (12.6)--15.1 (3.15)0.136 (22.0)2.92 (21.6)3020 (24.2)Vedolizumab \[[@CR232]\]10 mg/kg single-dose IVHealthy243 (9.07)--14.8 (7.38)0.139 (7.38)2.73 (35.2)4840 (12.8)Vedolizumab \[[@CR233]\]2 mg/kg IVUC54.0 (8.9)--15.1 (2.0)------Vedolizumab \[[@CR233]\]6 mg/kg IVUC154.3 (41.5)--22.0 (6.7)------Vedolizumab \[[@CR233]\]10 mg/kg IVUC279.0 (167.9)--20.6 (7.2)------Data are expressed as mean (standard deviation)*AUC* area under the curve, *Cl* clearance, *C*~*max*~ maximum concentration, *IV* intravenously, *T*~*max*~ time to reach maximum concentration, *UC* ulcerative colitis, *Vd* volume of distribution

A positive relationship between vedolizumab exposure and efficacy (clinical response and clinical remission) has been revealed for UC patients \[[@CR207], [@CR211]\]. Clinical remission rates at week 6 were comparable for patients with vedolizumab trough concentration \< 16 µg/ml and the placebo group \[[@CR211]\]. The GEMINI trial showed numerically higher clinical response and clinical remission rates at week 6 in UC patients with higher vedolizumab trough concentrations compared with patients without clinical response or remission \[[@CR207]\]. Almost 30% of patients with vedolizumab trough concentrations at week 6 of between 0 and 16.7 µg/ml achieved clinical response. With vedolizumab trough concentrations between 16.7 and 24.8 µg/ml, 47% of patients achieved a clinical response. Rosario et al. confirmed this finding in a post hoc analysis of all treated patients from the GEMINI trials. They demonstrated that higher baseline serum albumin, lower faecal calprotectin and no previous anti-TNF agent exposure were associated with an increased remission probability in UC patients \[[@CR211]\]. A population pharmacokinetic analysis of patients with CD and UC treated with vedolizumab showed similar pharmacokinetic parameters between CD and UC patients \[[@CR208]\]. Both body weight and albumin serum concentrations were influencing factors on clearance of vedolizumab. In this post hoc study, concomitant use of immunomodulators was not found to be of influence on the clearance of vedolizumab.

The pharmacodynamics of vedolizumab were assessed in a randomized controlled trial in patients with active UC \[[@CR212]\]. Patients were randomly assigned to a low-dose group (0.5 mg/kg), a high-dose group (2.0 mg/kg) or placebo. In both the low- and high-dose groups, saturation of α~4~ß~7~ on more than 90% of T-cells in the peripheral circulation was observed at weeks 4 and 6.

With regard to immunogenicity, ADAs for vedolizumab were detected in 4% of patients participating in the GEMINI-1 (UC patients) and GEMINI-2 (CD patients) trials during the first year of treatment. The use of concomitant immunomodulators reduced the rate of ADAs from 4 to 3%, a nonrelevant difference from a clinical point of view \[[@CR213]\]. Based on data from the ongoing GEMINI long-term safety study, the immunogenicity rate does not appear to increase over time \[[@CR213]\].

The potential benefit of applying TDM during vedolizumab treatment has to be determined as an optimal therapeutic range has not yet been defined. The results of a prospective observational trial with CD and UC patients showed an association between vedolizumab trough concentrations \< 18.5 μg/ml at week 6 and the need for extended therapy within the first 6 months \[[@CR214]\]. Nevertheless, adjustments in vedolizumab dosing are limited to adjustments in dosing interval since a fixed dose of 300 mg is used for all patients. After evaluation of a weight-based dose (6 mg/kg) in healthy volunteers, higher vedolizumab exposure was seen in patients with higher body weight \[[@CR215]\]. Weight-adjusted dosing in these patients overcompensated for exposure of vedolizumab, and subsequent phase III studies were therefore conducted with fixed-dose regimens. Although only extreme values of body weight were of clinically relevant influence on the clearance of vedolizumab, Rosario et al. have shown a clear association between higher bodyweight and increased clearance \[[@CR208]\]. This finding might support the use of vedolizumab dosing based on body weight, rather than a fixed dose, to optimize vedolizumab treatment.

Conclusion {#Sec16}
==========

An overview is provided of the pharmacokinetic and pharmacodynamic clinical considerations in the treatment of UC patients. Treatment of UC is discussed according to the classic step-up approach. For patients with mild to moderately active distal colitis, 5-ASA compounds are the preferred initial treatment. Combination treatment with both oral and topical 5-ASA is recommended in patients with mild to moderately active left-sided colitis. The efficacy of 5-ASA can be assessed by measuring local tissue concentrations via biopsies taken at endoscopy. Since this is rather impractical, this has no implications for clinical practice. Short-term use of corticosteroids, such as prednisone and budesonide, is appropriate in UC patients with moderate to severely active disease and in patients with mild activity who are intolerant or refractory to 5-ASA compounds. Treatment with CsA or tacrolimus can be a short-term alternative in patients with acute severe UC, refractory to corticosteroids, when a rapid onset is preferred as a bridge to the next treatment step. However, proven, effective, oral treatment with tacrolimus is a more potent calcineurin inhibitor compared with CsA and tacrolimus exhibits a less variable pharmacokinetic profile. For optimal clinical efficacy, trough concentrations for tacrolimus should be 10--15 ng/ml. Treatment with thiopurines is the next step in the step-up strategy of the treatment of active UC. 6-TGN concentrations \> 230 pmol/8 × 10^8^ (Lennard method) are associated with increased clinical response and remission rates, whereas 6-TGN concentrations \> 450 pmol/8 × 10^8^ (Lennard method) are associated with myelotoxicity. Lastly, treatment of UC has been greatly improved since the introduction of mAbs. In particular, the introduction of anti-TNF agents such as IFX and ADL led to higher clinical and endoscopic remission rates. However, a proportion of patients do not respond to induction treatment (primary nonresponders) and secondary loss of response is also not uncommon. Primary nonresponse to anti-TNF therapy can be associated with underdosing in the acute phase of disease, often combined with faecal loss through the ulcerated, 'leaky' gut. Secondary loss of response can be seen in patients with low serum drug levels, often in combination with the formation of ADAs. These factors, among factors associated with the clearance of mAbs, can be used in applying TDM. Since patients with lower albumin concentrations show higher IFX clearance, adjustments in dosing or dosing interval should be taken into account in patients with low albumin concentrations. The same applies for patients with detectable ADAs, where adjustments in dosing and dosing interval should be taken into account to potentially overcome these detectable ADAs. Additionally, the addition of concomitant immunomodulators (thiopurines/MTX) can overcome this detectable presence of ADAs. Vedolizumab, the latest addition to the biological treatment armamentarium for UC, is a humanized IgG1 mAb that targets α4ß7-integrine, which is present on T-cells in the lamina propria. Because of this gut-specific type of action, vedolizumab can be an option for UC patients not responding to anti-TNF therapy, or patients with recurrent infections due to the overall immunosuppressive side effect of anti-TNF therapy.

The focus of this review was the step-up strategy for the treatment of UC patients; however, in some patients, a top-down strategy should be the preferred option. This more aggressive approach, starting immediately with anti-TNF treatment, preferably in combination with an immunomodulator, might be needed in patients with acute severe UC. The benefit of early treatment with vedolizumab is still being investigated.
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